scholarly journals Switching Darunavir/Ritonavir to Darunavir/Cobicistat in Clinical Practice Experience with 150 patients through 48 weeks

2018 ◽  
Vol 4 (1) ◽  
Author(s):  
de la Fuente S ◽  
Díaz A ◽  
Vicente N ◽  
Ángel-Moreno A
Keyword(s):  
Clinical Practice ◽  
Practice Experience

Clinical Practice: Experience with newborn screening for congenital hypothyroidism in the Republic of Macedonia—a multiethnic country

2014 ◽  
Vol 174 (4) ◽  
pp. 443-448 ◽  
Author(s):  
Mirjana Kocova ◽  
Violeta Anastasovska ◽  
Elena Sukarova-Angelovska ◽  
Milica Tanaskoska ◽  
Elizabeta Taseva
Keyword(s):  
Clinical Practice ◽  
Newborn Screening ◽  
Congenital Hypothyroidism ◽  
Republic Of Macedonia ◽  
Practice Experience ◽  
The Republic

scholarly journals Special aspects of concentrated insulins: basic characteristics and research findings

2020 ◽  
Vol 22 (5) ◽  
pp. 481-490
Author(s):  
Tatiana Y. Demidova ◽  
Olga V. Balutina
Keyword(s):  
Clinical Practice ◽  
Insulin Glargine ◽  
Microvascular Complications ◽  
Severe Hypoglycemia ◽  
Glucose Lowering ◽  
Practice Experience ◽  
Patients With Diabetes ◽  
Research Findings ◽  
Basic Characteristics ◽  
Diabetic Microvascular Complications

The appearance of concentrated insulins in clinical practice determines the need to analyze product priorities in appropriate groups of patients with diabetes. The aim of this article is to summarize the literature on concentrated insulins (i.e. insulin lispro 200 units/mL, insulin degludec 200 units/mL, insulin glargine 300 units/mL) from randomized controlled trials, derive guidance on appropriate and safe use of these agents and demonstrate experience in real clinical practice. Severe hypoglycemia in all studies was generally low (though higher with prandial plus concentrated basal analogue therapy), and statistical improvements in other hypoglycemia categories were observed for concentrated basal insulins versus insulin glargine 100 units/mL. In all analyzed data hypoglycemic effect of insulin glargine 300 units/mL was equitable to insulin glargine 100 units/mL. Other important findings demonstrate more constant and prolonged insulin action with low within-subject/ between-day variability for insulin glargine 300 units/mL versus insulin glargine 100 units/mL, therefore, more physiological treatment might prevent from diabetic microvascular complications. The results of randomized trials are comparable with our clinical practice experience and indicate efficacious and safe glucose-lowering properties without risk of severe hypoglycemia.

scholarly journals PIN9 CLINICAL PRACTICE EXPERIENCE WITH TENOFOVIR ALAFENAMIDE (TAF) FOR TREATMENT OF HEPATITIS B IN THE US

2019 ◽  
Vol 22 ◽  
pp. S196
Author(s):  
M. Curry ◽  
H. Bae ◽  
D. Dieterich ◽  
V. Ankoma-Sey ◽  
R. Reddy ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Hepatitis B ◽  
Practice Experience ◽  
The Us ◽  
Tenofovir Alafenamide
Sign in / Sign up

Export Citation Format

Share Document